2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Squamous Cell Carcinoma of Head and Neck
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Lung Neoplasms
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumor
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Pheochromocytoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraganglioma, Extra-Adrenal
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma Metastatic
1
Osteosarcoma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
1
Gynecological Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Esophageal Squamous Cell Carcinoma
1
Digestive System Diseases
1
Interventions
Ifosfamide
30
Methotrexate
29
Doxorubicin
26
Cyclophosphamide
24
Cisplatin
22
Filgrastim
18
Etoposide
17
Gemcitabine
16
Leucovorin
14
Magnetic Resonance Spectroscopy
11
Temozolomide
10
Specimen Handling
10
cabozantinib
9
apatinib
9
X-Rays
9
Carboplatin
9
fludarabine
8
Radiotherapy
8
Nivolumab
8
Neoadjuvant Therapy
8
Irinotecan
8
Granulocyte Colony-Stimulating Factor
8
Drug Therapy
8
Docetaxel
8
Zoledronic Acid
7
Vincristine
7
Sirolimus
7
Phantoms, Imaging
7
Biopsy
7
mifamurtide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
penpulimab
×
Clear all
NCT06114225
2023-11-02
PROMIS
Ruijin Hospital
Phase 2
Recruiting
43 enrolled